Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Liabilities and Shareholders Equity (2020 - 2025)

Historic Liabilities and Shareholders Equity for GeneDx Holdings (WGS) over the last 6 years, with Q3 2025 value amounting to $493.9 million.

  • GeneDx Holdings' Liabilities and Shareholders Equity rose 2080.57% to $493.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 billion, marking a year-over-year increase of 1317.95%. This contributed to the annual value of $419.4 million for FY2024, which is 14.9% up from last year.
  • Latest data reveals that GeneDx Holdings reported Liabilities and Shareholders Equity of $493.9 million as of Q3 2025, which was up 2080.57% from $463.9 million recorded in Q2 2025.
  • GeneDx Holdings' Liabilities and Shareholders Equity's 5-year high stood at $933.3 million during Q2 2022, with a 5-year trough of $175.5 million in Q2 2021.
  • Its 5-year average for Liabilities and Shareholders Equity is $484.0 million, with a median of $463.9 million in 2025.
  • As far as peak fluctuations go, GeneDx Holdings' Liabilities and Shareholders Equity soared by 43168.35% in 2022, and later crashed by 4966.25% in 2023.
  • GeneDx Holdings' Liabilities and Shareholders Equity (Quarter) stood at $554.1 million in 2021, then decreased by 11.4% to $490.9 million in 2022, then decreased by 14.7% to $418.8 million in 2023, then rose by 0.15% to $419.4 million in 2024, then rose by 17.77% to $493.9 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $493.9 million for Q3 2025, versus $463.9 million for Q2 2025 and $446.4 million for Q1 2025.